

Steven Hirschfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7481354/publications.pdf>

Version: 2024-02-01

70
papers

2,912
citations

257450

24
h-index

168389

53
g-index

73
all docs

73
docs citations

73
times ranked

4055
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges in clinical trials for children and young people. Archives of Disease in Childhood, 2021, 106, 321-325.	1.9	21
2	Health Measurement Model—Bringing a Life Course Perspective to Health Measurement: The PRISM Model. Frontiers in Pediatrics, 2021, 9, 605932.	1.9	3
3	Prerequisites to support high-quality clinical trials in children and young people. Archives of Disease in Childhood, 2021, 106, 423-428.	1.9	4
4	Principles of Researching Health Disparities in Longitudinal Cohort Studies Enrolling Children. Frontiers in Pediatrics, 2021, 9, 627298.	1.9	3
5	What Could the Future of Safety Monitoring Look Like?. Therapeutic Innovation and Regulatory Science, 2019, 53, 590-600.	1.6	3
6	Weight estimation among multi-racial/ethnic infants and children aged 0–5–9 years in the USA: simple tools for a critical measure. Public Health Nutrition, 2019, 22, 147-156.	2.2	2
7	Assessment of a shortened informed consent form for pediatric research: a pilot study. Pediatric Research, 2018, 84, 516-519.	2.3	5
8	Introduction and Goals for the National Children’s Study. Frontiers in Pediatrics, 2018, 5, 240.	1.9	7
9	Immunization in pregnancy clinical research in low- and middle-income countries – Study design, regulatory and safety considerations. Vaccine, 2017, 35, 6575-6581.	3.8	22
10	Development of a Pediatric Adverse Events Terminology. Pediatrics, 2017, 139, .	2.1	20
11	Frameworks for Evaluating Medicines in Children. Clinical Therapeutics, 2017, 39, 1949-1958.	2.5	5
12	Global alignment of immunization safety assessment in pregnancy – The GAIA project. Vaccine, 2016, 34, 5993-5997.	3.8	72
13	Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women. Vaccine, 2016, 34, 5998-6006.	3.8	42
14	Predictive Models for Characterizing Disparities in Exclusive Breastfeeding Performance in a Multi-ethnic Population in the US. Maternal and Child Health Journal, 2016, 20, 398-407.	1.5	2
15	Improving the value of clinical research through the use of Common Data Elements. Clinical Trials, 2016, 13, 671-676.	1.6	93
16	Reframing clinical trial design and intervention development.. Journal of Clinical Oncology, 2016, 34, e14044-e14044.	1.6	0
17	Sponsors meet scientists to speed pediatric medicines development. Science Translational Medicine, 2015, 7, 279fs11.	12.4	3
18	A child is a child is a child? Paediatric terminology in a health context. Developmental Medicine and Child Neurology, 2015, 57, 985-985.	2.1	1

#	ARTICLE	IF	CITATIONS
19	Longer breastfeeding duration reduces the positive relationships among gestational weight gain, birth weight and childhood anthropometrics. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 632-638.	3.7	18
20	Harmonizing Biomarker Measurements in Longitudinal Studies of Children's Health and the Environment. <i>Biomonitoring</i> , 2014, 1, .	1.0	9
21	Meeting the Demand for Pediatric Clinical Trials. <i>Science Translational Medicine</i> , 2014, 6, 227fs11.	12.4	23
22	Paediatric drug development: The impact of evolving regulations. <i>Advanced Drug Delivery Reviews</i> , 2014, 73, 2-13.	13.7	124
23	Arm Span and Ulnar Length Are Reliable and Accurate Estimates of Recumbent Length and Height in a Multiethnic Population of Infants and Children under 6 Years of Age. <i>Journal of Nutrition</i> , 2014, 144, 1480-1487.	2.9	19
24	Building a Common Pediatric Research Terminology for Accelerating Child Health Research. <i>Pediatrics</i> , 2014, 133, 516-525.	2.1	35
25	Optimized DNA extraction from neonatal dried blood spots: application in methylome profiling. <i>BMC Biotechnology</i> , 2014, 14, 60.	3.3	41
26	A Federated Model of IRB Review for Multisite Studies: A Report on the National Children's Study Federated IRB Initiative. <i>IRB: Ethics & Human Research</i> , 2014, 36, 1-6.	0.8	26
27	The National Children's Study "A Proposed Plan. <i>New England Journal of Medicine</i> , 2013, 369, 1873-1875.	27.0	22
28	New Models for Large Prospective Studies: Is There a Better Way?. <i>American Journal of Epidemiology</i> , 2012, 175, 859-866.	3.4	110
29	The National Children's Study: An Opportunity for Medical Toxicology. <i>Journal of Medical Toxicology</i> , 2012, 8, 160-165.	1.5	16
30	HIV-1 infected monozygotic twins: a tale of two outcomes. <i>BMC Evolutionary Biology</i> , 2011, 11, 62.	3.2	10
31	National Children's Study: Update in 2010. <i>Mount Sinai Journal of Medicine</i> , 2011, 78, 119-125.	1.9	20
32	Pediatric Regulatory Initiatives. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 245-268.	1.8	37
33	Current Status of the National Children's Study. <i>Epidemiology</i> , 2010, 21, 605-606.	2.7	5
34	Accelerated Approval of Cancer Drugs: Improved Access to Therapeutic Breakthroughs or Early Release of Unsafe and Ineffective Drugs?. <i>Journal of Clinical Oncology</i> , 2009, 27, 4398-4405.	1.6	81
35	Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy. <i>Cytotherapy</i> , 2008, 10, 312-316.	0.7	11
36	Resource expectations for pediatric studies: Correlation of study type and patient number for FDA labeling. <i>Journal of Clinical Oncology</i> , 2008, 26, 6632-6632.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Progression-free survival as an end-point in clinical trials of biotherapeutic agents. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 23-28.	2.2	10
38	The Role of the FDA in Cancer Clinical Trials. , 2007, 132, 51-109.		1
39	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
40	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 491-505.	2.0	165
41	Pediatric Patients and Drug Safety. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 122-124.	0.6	4
42	A survey of phase I study designs of cellular, gene therapy and antigenic products for cancer at the US Food & Drug Administration. <i>Journal of Clinical Oncology</i> , 2005, 23, 6035-6035.	1.6	0
43	Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 701-703.	3.0	7
44	FDA Drug Approval Summaries: Oxaliplatin. <i>Oncologist</i> , 2004, 9, 8-12.	3.7	150
45	The pediatric research equity act and oncology. <i>Pediatric Blood and Cancer</i> , 2004, 43, 99-102.	1.5	3
46	Threshold of Credibility: A New Approach to Product Development for Metastatic Melanoma Therapy. <i>Journal of Immunotherapy</i> , 2004, 27, S55.	2.4	0
47	Threshold of Credibility: New Approach to Licensing Acute Leukemia Therapy.. <i>Blood</i> , 2004, 104, 3128-3128.	1.4	1
48	Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives. <i>Journal of Clinical Oncology</i> , 2003, 21, 1066-1073.	1.6	205
49	Oncology drug development: United States Food and Drug Administration perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 42, 137-143.	4.4	30
50	DEVELOPMENTAL THERAPEUTICS IN CHILDHOOD CANCER. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 631-655.	2.2	9
51	The FDA and The Lancet : an exchange. <i>Lancet, The</i> , 2001, 358, 415.	13.7	3
52	Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrozole, Paclitaxel, Bexarotene. <i>Oncologist</i> , 2001, 6, 4-11.	3.7	86
53	Pediatric Oncology: Regulatory Initiatives. <i>Oncologist</i> , 2000, 5, 441-444.	3.7	12
54	Working Group Session Report: Cancer. <i>Journal of Nutrition</i> , 1999, 129, 306S-307S.	2.9	3

#	ARTICLE	IF	CITATIONS
55	Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 417-421.	2.3	49
56	Pain as a Complication of HIV Disease. <i>AIDS Patient Care and STDs</i> , 1998, 12, 91-108.	2.5	13
57	Thyroid abnormalities in children infected with human immunodeficiency virus. <i>Journal of Pediatrics</i> , 1996, 128, 70-74.	1.8	34
58	Dysregulation of Growth and Development in HIV-Infected Children. <i>Journal of Nutrition</i> , 1996, 126, 2641S-2650S.	2.9	13
59	Dealing with Death: Visions of Those Who Left Too Soon. <i>American Journal of Nursing</i> , 1996, 96, 57.	0.4	0
60	Use of Human Recombinant Growth Hormone and Human Recombinant Insulin-Like Growth Factor-I in Patients with Human Immunodeficiency Virus Infection. <i>Hormone Research</i> , 1996, 46, 215-221.	1.8	24
61	Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways.. <i>Molecular and Cellular Biology</i> , 1993, 13, 2258-2268.	2.3	79
62	Inhibition of Estrogen-Responsive Gene Activation by the Retinoid X Receptor β : Evidence for Multiple Inhibitory Pathways. <i>Molecular and Cellular Biology</i> , 1993, 13, 2258-2268.	2.3	23
63	H-2RIIBP expressed from a baculovirus vector binds to multiple hormone response elements.. <i>Molecular Endocrinology</i> , 1992, 6, 219-230.	3.7	32
64	Selected issues in human immunodeficiency virus infection in adolescents. <i>Current Opinion in Pediatrics</i> , 1992, 4, 599-606.	2.0	2
65	Expression of major histocompatibility complex (MHC) class I genes in astrocytes correlates with the presence of nuclear factors that bind to constitutive and inducible enhancers. <i>Journal of Neuroimmunology</i> , 1992, 41, 35-42.	2.3	16
66	A constitutive damage-specific DNA-binding protein is synthesized at higher levels in UV-irradiated primate cells.. <i>Molecular and Cellular Biology</i> , 1990, 10, 2041-2048.	2.3	95
67	Cloned Trans-Acting Factors that Bind to the Regulatory Elements of the Major Histocompatibility Complex Class I Gene. , 1990, , 125-132.		1
68	Developmental and tissue-specific expression of nuclear proteins that bind the regulatory element of the major histocompatibility complex class I gene.. <i>Journal of Experimental Medicine</i> , 1989, 169, 1309-1321.	8.5	93
69	H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 8289-8293.	7.1	298
70	History of Children and the Development of Regulations at the FDA. , 0, , 6-15.		4